Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | L3MBTL3 | Q96JM7 | 6/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.38 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.35 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.34 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7003240 | 0.94 | MAPK1 (0.43) | MAPK1HTR6L3MBTL3L3MBTL1TP53BP1 | |
| SCHEMBL94206 | 0.94 | MAPK1 (0.43) | MAPK1HTR6L3MBTL3L3MBTL1TP53BP1 | |
| SCHEMBL5250892 | 0.94 | MAPK1 (0.43) | MAPK1HTR6L3MBTL3L3MBTL1TP53BP1 | |
| SCHEMBL863645 | 0.92 | MAPK1 (0.42) | MAPK1HTR6L3MBTL3L3MBTL1TP53BP1 | |
| SCHEMBL30475621 | 0.90 | MAPK1 (0.41) | MAPK1HTR6L3MBTL3L3MBTL1MEN1 | |
| SCHEMBL30761740 | 0.90 | MAPK1 (0.41) | MAPK1HTR6L3MBTL3L3MBTL1MEN1 | |
| SCHEMBL11008209 | 0.89 | MAPK1 (0.43) | MAPK1HTR6L3MBTL3L3MBTL1TP53BP1 | |
| SCHEMBL11003669 | 0.88 | MAPK1 (0.42) | MAPK1HTR6L3MBTL3L3MBTL1MEN1 | |
| SCHEMBL863778 | 0.85 | MAPK1 (0.43) | MAPK1HTR6L3MBTL3L3MBTL1OPRM1 | |
| SCHEMBL863893 | 0.83 | L3MBTL3 (0.41) | HTR6L3MBTL3L3MBTL1TP53BP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120025335-A | Alkaloid of skeleton type in nigella glandulifera seeds and preparation method and application thereof | 中国科学院新疆理化技术研究所 | 2025-05-23 | — | — | CN | disclosed |
| CN-115677723-B | 5-HT2A receptor antagonists and their use for treating central nervous system disorders | 瀚远医药有限公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-115677723-A | 5-HT2A receptor antagonists and their use for the treatment of central nervous system disorders | 瀚远医药有限公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-113214289-B | 5-HT2A receptor antagonists and their use for the treatment of central nervous system disorders | 瀚远医药有限公司 | 2022-10-28 | — | — | CN | disclosed |
| CN-113214289-A | 5-HT2A receptor antagonists and their use for the treatment of central nervous system disorders | 瀚远医药有限公司 | 2021-08-06 | — | — | CN | disclosed |
| WO-2021147818-A1 | 5-HT2A RECEPTOR ANTAGONIST AND APPLICATION THEREOF IN TREATING CENTRAL NERVOUS SYSTEM DISEASES | 瀚远医药有限公司 | 2021-07-29 | — | — | WO | disclosed |
| US-20190055204-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2019-02-21 | — | — | US | disclosed |
| US-20190055204-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2019-02-21 | — | — | US | disclosed |
| US-10077243-B2 | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2018-09-18 | — | — | US | disclosed |
| US-9902738-B2 | Compounds and methods for preventing, treating and/or protecting against sensory hair cell death | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2018-02-27 | — | — | US | disclosed |
| WO-2000006173-A1 | 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| EP-0978514-A1 | Indazole derivatives as 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 2000-02-09 | — | — | EP | disclosed |
| WO-2000000487-A1 | 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 2000-01-06 | — | — | WO | disclosed |
| WO-1999021856-A1 | AMINOMETHYL-BENZO[A]QUINOLIZIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC APPLICATIONS FOR NEURODEGENRATIVE DISEASES | PIERRE FABRE MEDICAMENT (FR) | 1999-05-06 | — | — | WO | disclosed |
| US-5874427-A | MIGRAINE | ELI LILLY AND COMPANY (US) | 1999-02-23 | — | — | US | disclosed |
| EP-0875513-A1 | Substituted heteroaromatic 5-HT 1F agonists | ELI LILLY AND COMPANY (US) | 1998-11-04 | — | — | EP | disclosed |
| WO-1998046570-A1 | SUBSTITUTED HETEROAROMATIC 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 1998-10-22 | — | — | WO | disclosed |
| EP-0710237-A1 | QUINOLIZIDINES WITH CALCIUM CHANNEL ANTAGONISTIC ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1996-05-08 | — | — | EP | disclosed |
| WO-1995003302-A1 | QUINOLIZIDINES WITH CALCIUM CHANNEL ANTAGONISTIC ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1995-02-02 | — | — | WO | disclosed |
| US-4236010-A | ANTIPYCHOTIC, ANTIEMENTIC, ANALGESIC | HOFFMANN-LA ROCHE INC. (US) | 1980-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10077243-B2 | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof | GRM5, GRIK5, GRM2 | MAPK1 3153/4885HTR6 115/4885L3MBTL3 4354/4885 |
| US-20190055204-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | GRM5, GRM2, GRM1 | MAPK1 1459/4885HTR6 130/4885L3MBTL3 3955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.